Myelodysplastic Syndromes: Diagnosis and Treatment

Mayo Clinic Proceedings

Volumn 90, Issue 7, 2015, Pages 969-983

  Steensma, David P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

DISEASE MANAGEMENT; HUMAN; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC AGENTS; DISEASE MANAGEMENT; HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; STEM CELL TRANSPLANTATION;

EID: 84934343560     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2015.04.001     Document Type: Review

References (101)

1. M.A. Sekeres The epidemiology of myelodysplastic syndromes Hematol Oncol Clin North Am 24 2 2010 287 294
2. J.W. Vardiman Hematopathological concepts and controversies in the diagnosis and classification of myelodysplastic syndromes Hematology Am Soc Hematol Educ Program 2006 199 204
3. D.P. Steensma, and J.M. Bennett The myelodysplastic syndromes: diagnosis and treatment Mayo Clin Proc 81 1 2006 104 130
4. S.H. Swerdlow, E. Campo, N.L. Harris, and et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 4th ed. 2008 IARC Press Lyon, France
5. X. Ma Epidemiology of myelodysplastic syndromes Am J Med 125 7 suppl 2012 S2 S5
6. X. Ma, M. Does, A. Raza, and S.T. Mayne Myelodysplastic syndromes: incidence and survival in the United States Cancer 109 8 2007 1536 1542
7. C.R. Cogle, M.R. Iannacone, D. Yu, and et al. High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment Leuk Res 38 1 2014 71 75
8. M. Xie, C. Lu, J. Wang, and et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies Nat Med 20 12 2014 1472 1478
9. S. Jaiswal, P. Fontanillas, J. Flannick, and et al. Age-related clonal hematopoiesis associated with adverse outcomes N Engl J Med 371 26 2014 2488 2498
10. Genovese G, Kähler AK, Rose SA, et al. Clonal hematopoiesis and cancer risk in blood derived DNA sequence. N Engl J Med. In press.
11. H. Van den Berghe, and L. Michaux 5q-, twenty-five years later: a synopsis Cancer Genet Cytogenet 94 1 1997 1 7
12. Z. Qian, J.M. Joslin, T.R. Tennant, and et al. Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia Chem Biol Interact 184 1-2 2010 50 57
13. C.M. Niemeyer, and I. Baumann Myelodysplastic syndrome in children and adolescents Semin Hematol 45 1 2008 60 70
14. C.J. Owen, C.L. Toze, A. Koochin, and et al. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy Blood 112 12 2008 4639 4645
15. C.N. Hahn, C.E. Chong, C.L. Carmichael, and et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia Nat Genet 43 10 2011 1012 1017
16. M.R. Savona, L. Malcovati, R. Komrokji, and et al. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults Blood 125 12 2015 1857 1865
17. P. Greenberg, C. Cox, M.M. LeBeau, and et al. International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 6 1997 2079 2088
18. R.J. Gibbons, A. Pellagatti, D. Garrick, and et al. Identification of acquired somatic mutations in the gene encoding chromatin-remodeling factor ATRX in the alpha-thalassemia myelodysplasia syndrome (ATMDS) Nat Genet 34 4 2003 446 449
19. A. Tefferi, and J.W. Vardiman Myelodysplastic syndromes N Engl J Med 361 19 2009 1872 1885
20. A. Manoharan, T. Brighton, R. Gemmell, K. Lopez, S. Moran, and P. Kyle Platelet dysfunction in myelodysplastic syndromes: a clinicopathological study Int J Hematol 76 3 2002 272 278
21. M.A. Boogaerts, V. Nelissen, C. Roelant, and W. Goossens Blood neutrophil function in primary myelodysplastic syndromes Br J Haematol 55 2 1983 217 227
22. R.T. Calado Immunologic aspects of hypoplastic myelodysplastic syndrome Semin Oncol 38 5 2011 667 672
23. M.G. Della Porta, L. Malcovati, E. Boveri, and et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes J Clin Oncol 27 5 2009 754 762
24. H. Wang, T. Chuhjo, S. Yasue, M. Omine, and S. Nakao Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome Blood 100 12 2002 3897 3902
25. D.P. Steensma Dysplasia has a differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors Curr Hematol Malig Rep 7 4 2012 310 320
26. A.A. van de Loosdrecht, T.M. Westers, A.H. Westra, A.M. Drager, V.H. van der Velden, and G.J. Ossenkoppele Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry Blood 111 3 2008 1067 1077
27. J. Schanz, C. Steidl, C. Fonatsch, and et al. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system J Clin Oncol 29 15 2011 1963 1970
28. P.L. Greenberg, H. Tuechler, J. Schanz, and et al. Revised international prognostic scoring system for myelodysplastic syndromes Blood 120 12 2012 2454 2465
29. R.P. Ketterling, W.A. Wyatt, S.A. VanWier, and et al. Primary myelodysplastic syndrome with normal cytogenetics: utility of "FISH panel testing" and M-FISH Leuk Res 26 3 2002 235 240
30. J. Pedersen-Bjergaard, M.K. Andersen, D.H. Christiansen, and C. Nerlov Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia Blood 99 6 2002 1909 1912
31. R. Bejar Clinical and genetic predictors of prognosis in myelodysplastic syndromes Haematologica 99 6 2014 956 964
32. R. Bejar, K.E. Stevenson, B. Caughey, and et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation J Clin Oncol 32 25 2014 2691 2698
33. P. Valent, B.J. Bain, J.M. Bennett, and et al. Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS Leuk Res 36 1 2012 1 5
34. New test developed at Dana-Farber/Brigham and Women's Cancer Center speeds treatment decisions for blood cancer patients. Dana-Farber Cancer Institute website. http://www.dana-farber.org/Newsroom/News-Releases/new-test-developed-at-dana-farber-brigham-and-womens-cancer-center-speeds-treatment-decisions-for-blood-cancer-patients.aspx. Publsihed November 11, 2014. Accessed March 1, 2015.
35. E. Papaemmanuil, M. Gerstung, L. Malcovati, and et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes Blood 122 22 2013 3616 3627 quiz 3699
36. M.G. Della Porta, L. Malcovati, C. Strupp, and et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome Haematologica 96 3 2011 441 449
37. F.P. Santos, H. Kantarjian, G. Garcia-Manero, and F. Ravandi The search for better prognostic models in myelodysplastic syndromes Curr Hematol Malig Rep 6 1 2011 13 21
38. L. Malcovati, M.G. Della Porta, C. Strupp, and et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS) Haematologica 96 10 2011 1433 1440
39. H. Kantarjian, S. O'Brien, F. Ravandi, and et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System Cancer 113 6 2008 1351 1361
40. G. Garcia-Manero, J. Shan, S. Faderl, and et al. A prognostic score for patients with lower risk myelodysplastic syndrome Leukemia 22 3 2008 538 543
41. R. Bejar, K. Stevenson, O. Abdel-Wahab, and et al. Clinical effect of point mutations in myelodysplastic syndromes N Engl J Med 364 26 2011 2496 2506
42. J. Boultwood, and J.S. Wainscoat Clonality in the myelodysplastic syndromes Int J Hematol 73 4 2001 411 415
43. B. Backx, L. Broeders, I. Touw, and B. Lowenberg Blast colony-forming cells in myelodysplastic syndrome: decreased potential to generate erythroid precursors Leukemia 7 1 1993 75 79
44. A. Raza, S. Gezer, S. Mundle, and et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes Blood 86 1 1995 268 276
45. M.H. Raaijmakers, S. Mukherjee, S. Guo, and et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia Nature 464 7290 2010 852 857
46. H.J. Deeg, and M. de Lima Hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes J Natl Compr Canc Netw 11 10 2013 1227 1233
47. M.A. Sekeres, and A.T. Gerds Established and novel agents for myelodysplastic syndromes Hematology Am Soc Hematol Educ Program 2014 1 2014 82 89
48. L. Malcovati, E. Hellstrom-Lindberg, D. Bowen, and et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet Blood 122 17 2013 2943 2964
49. P. Fenaux, and L. Ades How we treat lower-risk myelodysplastic syndromes Blood 121 21 2013 4280 4286
50. P. Fenaux, G.J. Mufti, E. Hellstrom-Lindberg, and et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Lancet Oncol 10 3 2009 223 232
51. M.A. Sekeres, and C. Cutler How we treat higher-risk myelodysplastic syndromes Blood 123 6 2014 829 836
52. R. Bejar, and D.P. Steensma Recent developments in myelodysplastic syndromes Blood 124 18 2014 2793 2803
53. M. Cazzola, M.G. Della Porta, and L. Malcovati Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes Hematology Am Soc Hematol Educ Program 2008 166 175
54. L. Malcovati Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes Leuk Res 31 suppl 3 2007 S2 S6
55. D.P. Steensma, and N. Gattermann When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes? Best Pract Res Clin Haematol 26 4 2013 431 444
56. D.P. Steensma The role of iron chelation therapy for patients with myelodysplastic syndromes J Natl Compr Canc Netw 9 1 2011 65 75
57. P. Armand, H.T. Kim, C.S. Cutler, and et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation Blood 109 10 2007 4586 4588
58. L. Pascal, O. Beyne-Rauzy, S. Brechignac, and et al. Cardiac iron overload assessed by T2∗magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients Br J Haematol 162 3 2013 413 415
59. A.F. List, M.R. Baer, D.P. Steensma, and et al. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome J Clin Oncol 30 17 2012 2134 2139
60. M.D. Cappellini, J. Porter, A. El-Beshlawy, and et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias Haematologica 95 4 2010 557 566
61. H. Kantarjian, F. Giles, A. List, and et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes Cancer 109 9 2007 1705 1714
62. S. Park, S. Grabar, C. Kelaidi, and et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience Blood 111 2 2008 574 582
63. V. Moyo, P. Lefebvre, M.S. Duh, B. Yektashenas, and S. Mundle Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis Ann Hematol 87 7 2008 527 536
64. D.P. Steensma Hematopoietic growth factors in myelodysplastic syndromes Semin Oncol 38 5 2011 635 647
65. E. Hellstrom-Lindberg, N. Gulbrandsen, G. Lindberg, and et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life Br J Haematol 120 6 2003 1037 1046
66. P. Greenberg, K. Taylor, R.A. Larson, and et al. Phase III randomized multicenter trial of recombinant human G-CSF in MDS [ASH abstract 196] Blood 82 11 suppl 1 1993 196a
67. M. Arshad, K. Seiter, J. Bilaniuk, and et al. Side effects related to cancer treatment: CASE 2. Splenic rupture following pegfilgrastim J Clin Oncol 23 33 2005 8533 8534
68. C.K. Brierley, and D.P. Steensma Thrombopoiesis-stimulating agents and myelodysplastic syndromes Br J Haematol 169 3 2015 309 323
69. M.A. Sekeres, A. Giagounidis, H. Kantarjian, and et al. Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes Br J Haematol 167 3 2014 337 345
70. A. Giagounidis, G.J. Mufti, P. Fenaux, and et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia Cancer 120 12 2014 1838 1846
71. M.E. Salacz, M.W. Lankiewicz, and D.E. Weissman Management of thrombocytopenia in bone marrow failure: a review J Palliat Med 10 1 2007 236 244
72. P.K. Epling-Burnette, J.S. Painter, D.E. Rollison, and et al. Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome Leukemia 21 4 2007 659 667
73. E.M. Sloand, C.O. Wu, P. Greenberg, N. Young, and J. Barrett Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy J Clin Oncol 26 15 2008 2505 2511
74. Y. Saunthararajah, R. Nakamura, R. Wesley, Q.J. Wang, and A.J. Barrett A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome Blood 102 8 2003 3025 3027
75. A. Raza, P. Meyer, D. Dutt, and et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes Blood 98 4 2001 958 965
76. A. Moreno-Aspitia, S. Geyer, C. Li, and et al. N998B: multicenter phase II trial of thalidomide (Thal) in adult patients with myelodysplastic syndromes (MDS) [abstract] Blood 100 2002 96a
77. T. Ito, H. Ando, T. Suzuki, and et al. Identification of a primary target of thalidomide teratogenicity Science 327 5971 2010 1345 1350
78. E.C. Fink, J. Kronke, S.N. Hurst, and et al. Lenalidomide induces ubiquitination and degradation of CSNK1A1 in MDS with Del(5q) [ASH abstract 4] Blood 124 21 2014 4
79. A. List, G. Dewald, J. Bennett, and et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion N Engl J Med 355 14 2006 1456 1465
80. R. Tehranchi, P.S. Woll, K. Anderson, and et al. Persistent malignant stem cells in del(5q) myelodysplasia in remission N Engl J Med 363 11 2010 1025 1037
81. A. Raza, J.A. Reeves, E.J. Feldman, and et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q Blood 111 1 2008 86 93
82. M.A. McDevitt Clinical applications of epigenetic markers and epigenetic profiling in myeloid malignancies Semin Oncol 39 1 2012 109 122
83. S.D. Gore In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment? Leuk Res 33 suppl 2 2009 S2 S6
84. R. Bejar, A. Lord, K. Stevenson, and et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients Blood 124 17 2014 2705 2712
85. R. Itzykson, O. Kosmider, T. Cluzeau, and et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias Leukemia 25 7 2011 1147 1152
86. S.D. Gore, P. Fenaux, V. Santini, and et al. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial Haematologica 98 7 2013 1067 1072
87. H. Kantarjian, J.P. Issa, C.S. Rosenfeld, and et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study Cancer 106 8 2006 1794 1803
88. M. Lubbert, S. Suciu, L. Baila, and et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group J Clin Oncol 29 15 2011 1987 1996
89. D.P. Steensma, M.R. Baer, J.L. Slack, and et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial J Clin Oncol 27 23 2009 3842 3848
90. M.T. Voso, M. Breccia, M. Lunghi, and et al. Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia Eur J Haematol 90 4 2013 345 348
91. T. Prebet, Z. Sun, M.E. Figueroa, and et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup Trial E1905 J Clin Oncol 32 12 2014 1242 1248
92. M.A. Sekeres, M. Othus, A.F. List, and et al. A randomized phase II study of azacitidine combined with lenalidomide or with vorinostat vs. azacitidine monotherapy in higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML): North American Intergroup Study SWOG S1117 [abstract 5] Blood 124 21 2014 5
93. T. Prebet, S.D. Gore, B. Esterni, and et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure J Clin Oncol 29 24 2011 3322 3327
94. E. Jabbour, G. Garcia-Manero, N. Batty, and et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy Cancer 116 6 2010 3830 3834
95. M.R. Litzow, S. Tarima, W.S. Perez, and et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia Blood 115 9 2010 1850 1857
96. M.G. Della Porta, E.P. Alessandrino, A. Bacigalupo, and et al. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R Blood 123 15 2014 2333 2342
97. C.S. Cutler, S.J. Lee, P. Greenberg, and et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome Blood 104 2 2004 579 585
98. J. Koreth, J. Pidala, W.S. Perez, and et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis J Clin Oncol 31 21 2013 2662 2670
99. A.T. Gerds, T.A. Gooley, E.H. Estey, F.R. Appelbaum, H.J. Deeg, and B.L. Scott Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS Biol Blood Marrow Transplant 18 8 2012 1211 1218
100. U. Platzbecker, M. Wermke, J. Radke, and et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial Leukemia 26 3 2012 381 389
101. P. Scheinberg, and D.P. Steensma Acquired marrow failure syndromes: aplastic anemia, paroxysmal nocturnal hemoglobinuria, and myelodysplastic syndromes D.P. Steensma, K.M. McCrae, eds. American Society of Hematology Self-Assessment Program (ASH-SAP) 5th ed. 2013 American Society of Hematology Washington, DC 369 400